Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on April 14, 2006
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
281/15/9987    most recent
M512714200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burgess, A.
Right arrow Articles by Gabrielli, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burgess, A.
Right arrow Articles by Gabrielli, B. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Papers In Press, published online ahead of print February 13, 2006
J. Biol. Chem, 10.1074/jbc.M512714200
Submitted on November 29, 2005
Accepted on February 13, 2006

Inhibition of S/G2 phase CDK4 reduces mitotic fidelity

Andrew Burgess, Matthew Wigan, Nichole Giles, Wanda DePinto, Paul Gillespie, Frankie Stevens, and Brian G. Gabrielli

Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland 4102

Corresponding Author: bgabrielli{at}cicr.uq.edu.au

CDK4/cyclin D has a key role in regulating progression through late G1 into S phase of the cell cycle. CDK4/cyclin D complexes then persist through the latter phases of the cell cycle, although little is known about their potential roles. We have developed small molecule inhibitors which are highly selective for CDK4 and have used these to define a role for CDK4/cyclin D in G2 phase. Addition of the CDK4 inhibitor or siRNA knockdown of cyclin D3, the cyclin D partner, delayed progression through G2 phase and mitosis. The G2 phase delay was independent of ATM/ATR and p38MAPK, but associated with elevated Wee1. The mitotic delay was due to failure of chromosomes to migrate to the metaphase plate. However, cells eventually exited mitosis, with a resultant increase in cells with multiple or micronuclei. Inhibiting CDK4 delayed the expression of the chromosomal passenger proteins survivin and borealin, although this was unlikely to account for the mitotic phenotype. These data provide evidence for a novel function for CDK4/cyclin D3 activity in S and G2 phase that is critical for G2/M progression and the fidelity of mitosis.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
W. DePinto, X.-J. Chu, X. Yin, M. Smith, K. Packman, P. Goelzer, A. Lovey, Y. Chen, H. Qian, R. Hamid, et al.
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
Mol. Cancer Ther., November 1, 2006; 5(11): 2644 - 2658.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement